Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	4.03B
Revenue (ttm)	292.81M
Net Income (ttm)	-805.51M
Shares Out	92.14M
EPS (ttm)	-8.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,513
Average Volume	192,719
Open	43.50
Previous Close	43.70
Day's Range	43.50 - 44.85
52-Week Range	37.05 - 54.90
Beta	0.53
RSI	46.19
Earnings Date	Mar 6, 2025

About Medeon Biodesign

Medeon Biodesign, Inc. researches, develops, manufactures, and sells medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site hernia...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2024, Medeon Biodesign's revenue was 292.81 million, an increase of 49.19% compared to the previous year's 196.26 million. Losses were -805.51 million, -33.13% less than in 2023.